This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

My new @ted.com talk from the main stage just went live!

go.ted.com/chrisbahl

🧵👇

We're #hiring a Scientist in Mass Spectrometry!

Apply today or share this post with your network: www.linkedin.com/jobs/view/42...
(ignore what linkedin says - the search is still open)

Interested? Please email your CV to: careers@aiproteins.bio

Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!

www.businesswire.com/news/home/20...

I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!

🧵👇

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

It was an honor to speak from the main stage at TED last week about our work at AI Proteins

Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics

Welcome Phil Brandish, Chief Development Officer, to the AI Proteins team!

www.businesswire.com/news/home/20...

We're delighted to share that our #Founder Chris Bahl @cdbahl.bsky.social is now our CEO!

So, I might have ended up on the jumbotron at the Celtics game proudly wearing my @aiproteins.bsky.social colors

Mireia Solà Colom, Head of Immunotherapeutics at AI Proteins, presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins

Exciting times at @aiproteins.bsky.social ! We are getting so close to see our drugs helping patients!
www.fiercebiotech.com/biotech/bris...

AI Proteins is excited to partner with @bms-news.bsky.social to develop novel miniprotein-based therapeutics. This collaboration will leverage our cutting-edge AI-driven platform to design and optimize miniproteins with the potential to transform patient outcomes
www.businesswire.com/news/home/20...

We've got some very exciting news to share!

businesswire.com/news/home/20...

and here's a 🧵 about the journey from academia to
@aiproteins.bsky.social

We're excited that Mireia Solà Colom, our Head of Immunotherapeutics will share some of our latest work on immune cell engagers at @bpdmc.bsky.social next month!

Our founder, President and CSO Chris Bahl @cdbahl.bsky.social went to the Falling Walls Science Summit last week to explain how we make #miniprotein therapeutics with unprecedented ability to control cellular behavior - you can check out the recording 👇
www.youtube.com/live/zB6-iUB...